1. Home
  2. CASI vs SHLT Comparison

CASI vs SHLT Comparison

Compare CASI & SHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • SHLT
  • Stock Information
  • Founded
  • CASI 1991
  • SHLT 1987
  • Country
  • CASI China
  • SHLT Israel
  • Employees
  • CASI N/A
  • SHLT N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • SHLT Business Services
  • Sector
  • CASI Health Care
  • SHLT Consumer Discretionary
  • Exchange
  • CASI Nasdaq
  • SHLT Nasdaq
  • Market Cap
  • CASI 58.8M
  • SHLT 49.7M
  • IPO Year
  • CASI 1996
  • SHLT N/A
  • Fundamental
  • Price
  • CASI $3.09
  • SHLT $3.10
  • Analyst Decision
  • CASI Strong Buy
  • SHLT Strong Buy
  • Analyst Count
  • CASI 1
  • SHLT 1
  • Target Price
  • CASI $6.00
  • SHLT $11.00
  • AVG Volume (30 Days)
  • CASI 56.2K
  • SHLT 56.9K
  • Earning Date
  • CASI 11-15-2024
  • SHLT 09-26-2024
  • Dividend Yield
  • CASI N/A
  • SHLT N/A
  • EPS Growth
  • CASI N/A
  • SHLT N/A
  • EPS
  • CASI N/A
  • SHLT N/A
  • Revenue
  • CASI $22,055,000.00
  • SHLT $55,939,000.00
  • Revenue This Year
  • CASI N/A
  • SHLT N/A
  • Revenue Next Year
  • CASI $134.79
  • SHLT N/A
  • P/E Ratio
  • CASI N/A
  • SHLT N/A
  • Revenue Growth
  • CASI N/A
  • SHLT N/A
  • 52 Week Low
  • CASI $2.05
  • SHLT $2.54
  • 52 Week High
  • CASI $8.19
  • SHLT $8.64
  • Technical
  • Relative Strength Index (RSI)
  • CASI 39.70
  • SHLT 53.11
  • Support Level
  • CASI $2.50
  • SHLT $2.90
  • Resistance Level
  • CASI $3.47
  • SHLT $3.19
  • Average True Range (ATR)
  • CASI 0.43
  • SHLT 0.31
  • MACD
  • CASI 0.07
  • SHLT 0.01
  • Stochastic Oscillator
  • CASI 39.80
  • SHLT 41.22

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About SHLT SHL Telemedicine Ltd

SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.

Share on Social Networks: